Aytu BioPharma reported first‑quarter fiscal 2026 results that beat consensus expectations, delivering a net income of $2.0 million and earnings per share of $0.21. Revenue totaled $13.9 million, a 16.5% decline from the $16.6 million reported in Q1 FY2025, but the company’s profit margin improved as net income rose 33% to $2.0 million from $1.5 million the prior year.
The revenue drop is largely attributable to a one‑time $3.3 million rebate that was recorded in the previous quarter. Excluding that rebate, the ADHD portfolio grew roughly 10%, while the pediatric portfolio fell from $1.3 million to $0.7 million, reflecting a shift in product mix and a temporary slowdown in that segment.
Adjusted EBITDA was negative $0.6 million, a result of $32.6 million in launch‑related investments for the first‑in‑class antidepressant EXXUA. Cash balances stood at $32.6 million as of September 30 2025, providing a cushion for the upcoming launch, though a separate report noted a conflicting figure of $1 million, highlighting the need for careful monitoring of liquidity disclosures.
Management emphasized that EXXUA, a selective serotonin 5HT1a receptor agonist, is slated for a Q4 2025 launch and that the company remains on track to enter the $22 billion U.S. major depressive disorder market. A method‑of‑use patent for EXXUA has been extended to September 2 2030, reinforcing the company’s competitive moat.
Analysts had projected earnings per share of –$0.20 and revenue of $12.6 million for the quarter. A $0.21 EPS represents a $0.41 beat, while revenue exceeded estimates by $1.3 million. No market‑reaction data were available, but the strong earnings beat and the launch momentum suggest a positive outlook for the company’s growth trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.